External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology ARVO 2023
Roche and Genentech at

ARVO 2023

April 23 - April 28
New Orleans, USA
arvo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Apr 28 / Roche and Genentech
Clustering and Treatment Patterns in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A United States Claims Database Study
This poster presentation describes results from an observational study conducted using MarketScan claims databases of patients with nAMD and DME treated with anti-VEGF injection from Janurary- 1, 2017 - July 1, 2018 and followed for 2 years. Cluster analysis identified three groups within each disease that were separated by treatment characteristics. Payer and insurance type differed by cluster and may be associated with treatment patterns.
Ophthalmology Diabetic Macular Edema Neovascular Age Related Macular Degeneration ARVO-2023

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 28 / Roche and Genentech
Deep learning segmentation of foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) of nonproliferative diabetic retinopathy
Diabetic retinopathy (DR) is a common complication of diabetes that can lead to vision loss if not adequately treated. DR progression can be monitored using optical coherence tomography angiography (OCTA) to identify changes in foveal vascular density (VD) and foveal avascular zone (FAZ) enlargement. Although automated FAZ measurements using OCTA device software are quicker than manual FAZ segmentation, they are not always reliable in eyes with DR and may require manual correction. This study examines whether FAZ area segmentation in OCTA with deep learning (DL) can be improved by adding supervised auxiliary tasks (FAZ boundary and/or retinal vessel mask).
Ophthalmology Diabetic Retinopathy Artificial Intelligence Deep learning Machine Learning Imaging ARVO-2023

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 28 / Roche and Genentech
Relationship between Retinal Structural Abnormalities and Visual Outcomes in Diabetic Macular Edema: Phase 2 Boulevard Trial
Diabetic macula edema (DME) is the leading cause of vision loss among people with diabetes. Retinal structural abnormalities (key features of DME) can be detected using optical coherence tomography (OCT). However, the relationship between individual retinal structural abnormalities and visual function in eyes with DME is unclear. This study examines the relationship between retinal structural abnormalities and visual function in eyes with DME enrolled in the phase 2 BOULEVARD trial (NCT02699450).
Ophthalmology Diabetic Macular Edema Color Fundus Photography Artificial Intelligence Deep learning Machine Learning Imaging Visual Acuity Gain ARVO-2023
12:45 PM
Duration 15mins La Nouvelle AB
Durable vision gains and greater fluid control with extended faricimab▼ dosing versus aflibercept in patients with diabetic macular edema
Lim J, Chen SJ, Steinle N, Jaffe G, Gerendas B, Abreu F, Camino A, Gibson K, Jain N, Shildkrot E, Souverain A, Tang Y, Willis J, Haskova Z
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 PM
Duration 15mins La Nouvelle AB
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema
Goldberg R, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Shildkrot E, Amador M, Mar F
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:15 PM
Duration 15mins La Nouvelle AB
Faster time to retinal fluid control with faricimab▼ in patients with DME in the phase 3 YOSEMITE/RHINE trials
Pollreisz A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 15mins La Nouvelle AB
Port Delivery System With Ranibizumab in the Treatment of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial
Emanuelli A, Holekamp N, Latkany P, Brittain C, Quezada-Ruiz C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Malhotra V, Pieramici D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 15mins La Nouvelle AB
Visual function loss in geographic atrophy: learnings from lampalizumab trial data
Steffen V, Anegondi N, Ferrara D, Chakravarthy U
Ophthalmology | Geographic Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:45 AM
Duration 15mins La Nouvelle AB
Individualized faricimab▼ dosing up to every 16 weeks maintains robust anatomic and vision outcomes through 2 years in nAMD
Chaudhary V, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 AM
Duration 15mins La Nouvelle AB
A novel intravitreal anti-IL-6 monoclonal antibody for UME: preliminary results from the phase 1 DOVETAIL study
Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M
Ophthalmology | Uveitis - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.